Correlation between pharmacokinetics and pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Noradrenaline Reuptake Inhibitors and maternal and neonatal outcomes: Results from a naturalistic study in patients with affective disorders,Human Psychopharmacology: Clinical and Experimental

当前位置： X-MOL 学术 › Human Psychopharmacology: Clinical and Experimental › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Correlation between pharmacokinetics and pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Noradrenaline Reuptake Inhibitors and maternal and neonatal outcomes: Results from a naturalistic study in patients with affective disorders
Human Psychopharmacology: Clinical and Experimental ( IF 1.672 ) Pub Date : 2020-11-30 , DOI: 10.1002/hup.2772
Anna Colombo ₁ , Francesca Giordano ₂ , Federica Giorgetti ₁ , Ilaria Di Bernardo ₁ , Monica F Bosi ₁ , Alberto Varinelli ₁ , Rita Cafaro ₁ , Paola Pileri ₃ , Irene Cetin ₃ , Emilio Clementi _{4,

5} , Caterina A Viganò ₁ , Bernardo Dell'Osso _{1,

6,

7}

Affiliation

Some studies have linked the use of selective serotonin reuptake inhibitors and selective serotonin and noradrenaline reuptake inhibitors (SSRIs/SNRIs) to the risk of perinatal complications. This study explored the relationship between pharmacokinetics and pharmacogenetics, SSRIs/SNRIs tolerability and effectiveness and maternal and newborn outcomes.

中文翻译：

选择性5-羟色胺再摄取抑制剂和选择性5-羟色胺和去甲肾上腺素再摄取抑制剂的药代动力学和药物遗传学与母婴结局之间的相关性：情感障碍患者的自然研究结果

一些研究已将选择性血清素再摄取抑制剂和选择性血清素和去甲肾上腺素再摄取抑制剂 (SSRIs/SNRIs) 的使用与围产期并发症的风险联系起来。本研究探讨了药代动力学和药物遗传学、SSRIs/SNRIs 耐受性和有效性以及孕产妇和新生儿结局之间的关系。

更新日期：2020-11-30

点击分享查看原文

点击收藏